Systemic therapy for Unresectable Hepatocellular Carcinoma: Therapeutic Effectiveness by Treatment Modality and Optimal Drug Use Order
Not Applicable
- Conditions
- nresectable hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000051797
- Lead Sponsor
- Japanese Red Cross Society Himeji Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who refuse to use clinical data (blood samples, imaging, pathology).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival since induction of systemic therapy.
- Secondary Outcome Measures
Name Time Method The following data were collected for each regimen: Overall survival, Progression free survival, Time to Progression, post-progression survival, anti-tumor effect, complication frequency, changes in liver reserve and nutritional indices during systemic chemotherapy, changes in tumor markers, changes in physical examination findings, rate of progression to post-progression therapy, and the presence or absence of curative surgery or local therapy after tumor shrinkage and its effect. Clinical data indicators related to life prognosis, treatment response, and occurrence of side effects will be used to construct a treatment selection decision index using AI.